Liquidia Corporation - Common Stock (NQ:LQDA)

44.82 +2.17 (+5.09%)

Delayed Quote Updated: 12:12 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Liquidia Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It ↗

August 12, 2025

The company is working through a patent battle that could seriously hamper sales of its new drug.

Via Investor's Business Daily

Topics Intellectual Property

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 12, 2025

Via Benzinga

Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12, 2025

From Liquidia Technologies, Inc.

Via GlobeNewswire

Earnings Preview For Liquidia ↗

August 11, 2025

Via Benzinga

These Analysts Boost Their Forecasts On Liquidia ↗

May 28, 2025

Via Benzinga

Breaking Down Liquidia: 12 Analysts Share Their Views ↗

May 28, 2025

Via Benzinga

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025

August 05, 2025

From Liquidia Technologies, Inc.

Via GlobeNewswire

Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? ↗

July 24, 2025

Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it.

Via Investor's Business Daily

Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™

June 23, 2025

From Liquidia Technologies, Inc.

Via GlobeNewswire

Dow Gains 50 Points; US Small Business Optimism Index Rises In May ↗

June 10, 2025

Via Benzinga

Topics Stocks

10 Health Care Stocks Whale Activity In Today's Session ↗

June 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

June 10, 2025

Via Benzinga

Which stocks are moving on Tuesday? ↗

June 10, 2025

Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Which stocks are gapping on Tuesday? ↗

June 10, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia ↗

June 10, 2025

Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment.

Via Investor's Business Daily

These stocks that are showing activity before the opening bell on Tuesday. ↗

June 10, 2025

Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

June 10, 2025

Via Benzinga

Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday ↗

June 02, 2025

Via Benzinga

Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD

June 02, 2025

From Liquidia Technologies, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 30, 2025

Via Benzinga

Friday's after hours session: top gainers and losers ↗

May 30, 2025

After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge ↗

May 27, 2025

Liquidia gains FDA approval for Yutrepia to treat PAH and PH-ILD, with funding in place despite ongoing patent litigation with United Therapeutics

Via Benzinga

Topics Intellectual Property

Liquidia Retail Buzz Surges After BofA Raises Price Target to $25 On Yutrepia FDA Nod ↗

May 27, 2025

The company’s proprietary dry-powder formulation, supported by Phase 3 data, is viewed as a promising alternative to United Therapeutics’ Tyvaso, though legal challenges remain pending.

Via Stocktwits

Topics Intellectual Property

Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference

May 28, 2025

From Liquidia Technologies, Inc.

Via GlobeNewswire

U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

May 23, 2025

From Liquidia Technologies, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 19, 2025

Via Benzinga

Where Liquidia Stands With Analysts ↗

May 12, 2025

Via Benzinga

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics

May 12, 2025

From Liquidia Corporation

Via GlobeNewswire

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 08, 2025

From Liquidia Corporation

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.